Aeglea Bio Therapeutics Inc represents a commitment to innovation, scientific excellence, and improving patients' lives. With a focus on developing transformative therapies, Aeglea Bio Therapeutics is dedicated to addressing unmet medical needs in the field of rare genetic diseases. The company's corporate philosophy revolves around leveraging their expertise in human enzyme biology to develop novel therapeutic solutions. Aeglea Bio Therapeutics believes in fostering strong collaborations, utilizing cutting-edge technologies, and advancing patient-centric approaches. By combining their passion for scientific discovery with a patient-driven mindset, Aeglea Bio Therapeutics strives to make a meaningful impact in the lives of individuals affected by rare diseases.

Aeglea Bio Therapeutics Inc is primarily present in the United States of America.

Aeglea Bio Therapeutics Inc has achieved significant milestones since its inception. Notably, the company successfully completed a Phase 1 clinical trial for its lead product candidate, AEB1102, demonstrating its safety and tolerability. Aeglea also received Fast Track Designation from the FDA for AEB1102 in combination with pembrolizumab for the treatment of cancer. In addition, the company expanded its pipeline by initiating a Phase 1/2 trial for AEB3103 in patients with Arginase 1 Deficiency, a rare genetic disorder. These achievements highlight Aeglea Bio Therapeutics Inc's commitment to developing innovative therapies and addressing unmet medical needs.

Aeglea Bio Therapeutics Inc, a leading biotechnology company, was founded in 2013 and is headquartered in Austin, Texas. The company focuses on developing innovative therapeutics to improve the lives of patients with rare genetic diseases and cancer. Aeglea Bio Therapeutics utilizes its proprietary technology platform, known as Aeglea's Engineered Human Enzyme Products (HEPs), to design and manufacture therapeutic enzymes. These enzymes are developed to target and degrade specific amino acids in the body, addressing the underlying metabolic imbalances associated with certain diseases. With a strong research and development pipeline, Aeglea Bio Therapeutics aims to provide patients with breakthrough treatments that have the potential to transform their lives.

The main competitors of Aeglea Bio Therapeutics Inc in the market include companies such as Amgen, Incyte Corporation, and bluebird bio. These companies operate in the biopharmaceutical industry and also focus on the development of innovative therapies and treatments. Aeglea Bio Therapeutics Inc, based in the United States, is known for its research in the field of human biochemistry and genetic insights to develop transformative medicines. As it continues to strive for advancements in the industry, it faces competition from these industry leaders in delivering cutting-edge solutions for various diseases and medical conditions.

Aeglea Bio Therapeutics Inc is primarily active in the biotechnology and pharmaceutical industries.

Aeglea Bio Therapeutics Inc is a biotechnology company with a unique business model focused on developing therapeutic enzymes to treat rare genetic diseases and certain cancers. By leveraging its proprietary technology platform, Aeglea engineers enzymes to degrade specific amino acids in the body associated with these diseases, aiming to restore balance and improve patient outcomes. Through targeted enzyme therapy, Aeglea seeks to address significant unmet medical needs and create value for patients, healthcare providers, and shareholders.

Aeglea Bio Therapeutics KGV ir -14,03.

Aeglea Bio Therapeutics KUV ir 9,85.

AlleAktien kvalitātes vērtējums Aeglea Bio Therapeutics ir 1/10.

gaidāmā Aeglea Bio Therapeutics apgrozījums ir 13,60 milj. USD.

gaidāmā Aeglea Bio Therapeutics peļņa ir -9,55 milj. USD.

Aeglea Bio Therapeutics Inc. is an innovative biotechnology company based in Austin, Texas. The company was founded in 2013 and specializes in the development of therapies for rare genetic disorders. Aeglea Bio Therapeutics has a unique business model based on two pillars: the development of new drugs and collaboration with other companies and research institutions. The first pillar of Aeglea Bio Therapeutics' business model is the development of therapies for rare genetic disorders. This is achieved through the research of the role of amino acids in metabolism and their effects on specific diseases. The company utilizes innovative technologies to identify and develop new treatment approaches. This includes the production of enzymes that selectively break down certain amino acids, thereby reducing or removing disease-causing substances. The first drug developed by Aeglea Bio Therapeutics is Pegzilarginase (AEB1102), an enzyme replacement therapy for the treatment of Arginase-1 deficiency, a rare genetic disease. The second pillar of Aeglea Bio Therapeutics' business model is collaboration with other companies and research institutions. The company works with various partners in the field of research and development to accelerate the development of new drugs. Aeglea Bio Therapeutics also collaborates with biopharmaceutical companies and other organizations to bring its technologies and products to market. For example, the company has announced a partnership with Merck Sharp & Dohme Corp. (MSD) to develop combination therapy for the treatment of certain types of cancer. Aeglea Bio Therapeutics currently offers only one product, Pegzilarginase (AEB1102), which is in the clinical phase. However, the company plans to expand its portfolio by developing additional enzyme replacement therapies and treating a broader range of genetic disorders. The company has also developed a diagnostic test for quick and easy diagnosis of Arginase-1 deficiency. The business model of Aeglea Bio Therapeutics is focused on developing and commercializing innovative therapies for rare genetic disorders. The company relies on close collaboration with other partners in the field of research and development and the use of innovative technologies.

Aeglea Bio Therapeutics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Aeglea Bio Therapeutics vai uzņēmums nedod dividendes.

Aeglea Bio Therapeutics ISIN ir US00773J1034.

Aeglea Bio Therapeutics WKN ir A2AG5H.

Aeglea Bio Therapeutics simbols ir AGLE.

Pēdējo 12 mēnešu laikā Aeglea Bio Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Aeglea Bio Therapeutics plāno maksāt dividendes 0 USD apmērā.

Aeglea Bio Therapeutics pašreizējā dividendu rentabilitāte ir .

Aeglea Bio Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Aeglea Bio Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Aeglea Bio Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Aeglea Bio Therapeutics apmērā 0 USD, kas tika izmaksāta 16.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 16.09.2024..

Pēdējās dividendes izmaksa notika 16.09.2024..

Gadā 2023, Aeglea Bio Therapeutics izmaksāja 0 USD dividendes.

Aeglea Bio Therapeutics dividendes tiek izmaksātas USD.